Abstract Search

ea0037ep120 | Steroids, development and paediatric endocrinology | ECE2015

Six-month interim safety and efficacy of different dose levels of transCon hGH administered once weekly versus standard daily human growth hormone replacement therapy in pre-pubertal children with growth hormone deficiency (GHD)

Chatelain Pierre , Malievsky Oleg , Radziuk Klaudziya , Elsedfy Heba Hassan , Mikhailova Evgenia , Beckert Michael

Background: TransCon hGH is a long-acting prodrug of recombinant human GH (hGH) that releases into the blood compartment fully active unmodified hGH. TransCon hGH was shown in two Phase 1 studies and a Phase 2 study in AGHD to be safe and well tolerated and inducing an IGF-I pharmacodynamic response within the normal range throughout the dosing period. This interim analysis consists of 25 patients completing all 6 months of treatment.Objectives: The obje...

1 shares

ePoster

ea0090p432 | Pituitary and Neuroendocrinology | ECE2023

Design of the foresiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly Lonapegsomatropin to Placebo and Daily Somatropin in Adults with Growth Hormone Deficiency (GHD)

Gilis-Januszewska Aleksandra , Fleseriu Maria , Otto Jorgensen Jens , CJ Yuen Kevin , Hoybye Charlotte , Mao Meng , Kang Jennifer , Song Wenjie , Komirenko Allison , Shu Aimee , Beckert Michael

Background: Adult GHD results from insufficient growth hormone (GH) secretion from the anterior pituitary gland and may represent either a continuation of childhood-onset GHD or GHD acquired during adulthood. Clinically, adult GHD is associated with central adiposity, decreased lean muscle mass, increased fat mass, decreased bone mineral density, and reduced quality of life. Current standard of care consists of GH replacement via daily injections. Lonapegsomatropin (SKYTROFA; ...

0 shares

ea0073oc6.6 | Oral Communications 6: Calcium and Bone | ECE2021

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

Schwarz Peter , Rejnmark Lars , Rubin Mishaela , Vokes Tamara J. , Clarke Bart L. , Ahmed Intekhab , Palermo Andrea , Marcocci Claudio , Pagotto Cristina , Eriksen Erik , Mourya Sanchita , Markova Denka , Pihl Susanne , Shu Aimee , Beckert Michael , Khan Aliya

BackgroundHypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiologic levels of calcitriol, promoting independence from Ca and active vitamin D supplements and normalization of QoL. TransCon PTH is an investigational long-acting p...

0 shares

Endocrine Abstracts

Six-month interim safety and efficacy of different dose levels of transCon hGH administered once weekly versus standard daily human growth hormone replacement therapy in pre-pubertal children with growth hormone deficiency (GHD)

Design of the foresiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly Lonapegsomatropin to Placebo and Daily Somatropin in Adults with Growth Hormone Deficiency (GHD)

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

BiosciAbstracts